Supriya Lifescience said proceedings were initiated against the personnel of the company under the NDPS Act, 1985 for a procedural lapse for a single export transaction of an identified producer.
The company's management said improved capacity utilisation, expansion in global markets, and contribution from newly launched products supported growth during the financial year 2025-26.
Stocks to buy: Kunal Kamble of Bonanza suggests buying Siemens Energy, Supriya Lifescience and Exide Industries